1. Home
  2. XGN vs LUNG Comparison

XGN vs LUNG Comparison

Compare XGN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$2.70

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
LUNG
Founded
2002
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
57.9M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
XGN
LUNG
Price
$2.70
$1.27
Analyst Decision
Strong Buy
Buy
Analyst Count
7
7
Target Price
$8.86
$5.38
AVG Volume (30 Days)
177.8K
338.9K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
$8.12
$2.48
Revenue Next Year
$13.00
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$2.59
$1.13
52 Week High
$12.23
$5.46

Technical Indicators

Market Signals
Indicator
XGN
LUNG
Relative Strength Index (RSI) 34.43 40.15
Support Level $2.59 $1.13
Resistance Level $3.29 $1.64
Average True Range (ATR) 0.17 0.10
MACD -0.01 -0.00
Stochastic Oscillator 12.05 10.79

Price Performance

Historical Comparison
XGN
LUNG

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: